Loading...

Home
ETF
GTBP

GTBP

-

$

0.000

0.000(0.000%)

At close

0.000(0.000%)Aft-market

ET

$

0.000

0.000(0.000%)

At close

0.000(0.000%)Aft-market

ET

Overview Technical News

Most Trusted AI Platform for Winning Trades

Copyright © 2026 Intellectia.AI. All Rights Reserved.

Company

Home
Contact
About Us
Press
Privacy
Terms of Service
Service Terms of Use

Resources

Blog
Tutorial
Help Center
Affiliate Program

Markets

Market Analysis
Crypto
Featured Screeners
AI Earnings Calendar
Market Movers
Stock Monitor
Economic Calendar
All US Stocks
All Cryptos

Tools

Dividend Calculator
Dividend Yield Calculator
Options Profit Calculator

Features

QuantAI Alpha Pick
SwingMax Portfolio
Swing Trading
AI Stock Picker
Whales Auto Tracker
Daytrading Center
Patterns Detection
AI Screener
Financial AI Agent
Backtesting Playground
AI Earnings Prediction
Stock Monitor
Technical Analysis

News

Overview
Top News
Daily Market Brief
Earnings Analysis
Newswire
Stock News
Crypto News
Institution News
Congress News
Monitor News

Compare

TradingView
SeekingAlpha

GTBP News

GT Biopharma Advances NK Cell Therapy with TriKE Platform

Jun 12 2026Globenewswire

GT Biopharma Advances NK Cell Therapy with TriKE Platform

Jun 12 2026Newsfilter

GT Biopharma Advances Three Drug Candidates into Clinical Trials

Jun 08 2026Globenewswire

GT Biopharma Advances Three Cancer Drug Candidates into Clinical Trials

Jun 08 2026Newsfilter

GT Biopharma Enters Clinical Trials with Three Drugs

Jun 02 2026Newsfilter

GT Biopharma: Three Drugs Enter Human Trials

May 29 2026PRnewswire

GT Biopharma Advances Three Drug Candidates in Clinical Trials

May 29 2026Newsfilter

GT Biopharma Advances NK Cell Immunotherapy with TriKE Candidates

May 19 2026Newsfilter

GT Biopharma Initiates GTB-5550 Clinical Trial for B7-H3 Targeting

May 18 2026PRnewswire

GT Biopharma Doses First Patient in GTB-5550 Clinical Trial

May 18 2026Newsfilter

GT Biopharma Reports Q2 2026 Financial Results

May 15 2026seekingalpha

GT Biopharma Initiates Phase 1 Trial of GTB-5550 for Solid Tumors

May 14 2026Newsfilter

GT Biopharma Launches Clinical Trial for B7-H3 Targeted Therapy

May 14 2026Newsfilter

GTB-5550 Enters Clinical Trials for Solid Tumors

May 14 2026Newsfilter

GT Biopharma Reports $28.4 Million Net Loss for FY2025

Mar 02 2026seekingalpha

GT Biopharma Initiates Phase 1 Trial for GTB-5550

Feb 03 2026Newsfilter